---
schema_version: "secwatch.filing_event.v1"
accession: "0000849146-24-000048"
form_type: "8-K"
ticker: "LFVN"
cik: "0000849146"
company_name: "Lifevantage Corp"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T01:18:25.637031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LifeVantage Q3 revenue falls 10.2% to $48.2M; guidance cut; adjusted EBITDA up 55%

## Summary
- Revenue $48.2M, down 10.2% YoY; Americas -5.9%, Asia/Pacific & Europe -22.4% (constant currency -16.1%).
- GAAP EPS $0.13, adjusted EPS $0.21 vs $0.08 a year ago; adjusted EBITDA $5.1M, up 54.7%.
- Fiscal 2024 revenue guidance lowered to $202-205M from $207-213M; adjusted EBITDA guidance unchanged at $16-18M.
- Declared $0.04/share cash dividend payable June 14, 2024 to holders of record May 31, 2024.
- Repurchased 0.3M shares for $1.9M in Q3; $22.3M remaining under buyback program; cash $17.4M, no debt.

## SEC filing metadata
- accession: 0000849146-24-000048
- form_type: 8-K
- ticker: LFVN
- cik: 0000849146
- company_name: Lifevantage Corp
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/0000849146-24-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/lfvn-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000849146-24-000048
- JSON: https://secwatch.observer/filing/0000849146-24-000048.json
- Plain text: https://secwatch.observer/filing/0000849146-24-000048.txt

## Key facts
- Earnings Releases
  Lifevantage Corp reported three and nine months ended March 31, 2024 results: revenue $48.2 million, net income $1.7 million, EPS $0.13 per diluted share. Guidance lowered.
  - Period: three and nine months ended March 31, 2024
  - Revenue: $48.2 million
  - Net income: $1.7 million
  - EPS: $0.13 per diluted share
  - Guidance: lowered
  - Result: reported results
  source text: health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2024. Third Quarter Fiscal 2024 Summary*: • Revenue of $48.2 million, a decrease of 10.2% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue was down approximately 8.7%; • Revenue in
  evidence_url: https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/0000849146-24-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.